A study reviewing the potential role of PSCA proposed that expression of the gene is regulated through the androgen receptor complex.[7] The proteins translated from the gene, is then glycosylated in the ER, and transported to the cell membrane where it is connected to a lipid.[7] This results in the formation of a GPI-anchored proteins, these proteins can be often secreted by cells or play a role in cell signaling. While, the ligand activating PSCA or the downstream physiological role has not yet been determined, because of its mechanism and over expression in prostate cancer cells, PSCA can potentially serve as a biomarker for detecting cancer.[8]
Bahrenberg G, Brauers A, Joost HG, Jakse G (September 2000). "Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors". Biochemical and Biophysical Research Communications. 275 (3): 783–8. doi:10.1006/bbrc.2000.3393. PMID10973799.
Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, et al. (June 2001). "Prostate stem cell antigen is overexpressed in human transitional cell carcinoma". Cancer Research. 61 (12): 4660–5. PMID11406532.
Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, et al. (May 2002). "Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate". Cancer Research. 62 (9): 2546–53. PMID11980648.
Tran CP, Lin C, Yamashiro J, Reiter RE (December 2002). "Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells". Molecular Cancer Research. 1 (2): 113–21. PMID12496358.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. (April 2005). "Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer". Nature Genetics. 37 (4): 391–400. doi:10.1038/ng1531. PMID15765097. S2CID27245550.
Zhigang Z, Wenlu S (December 2005). "Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma". The Prostate. 65 (4): 299–305. doi:10.1002/pros.20290. PMID16015594. S2CID1951165.
Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, et al. (August 2005). "Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer". Pancreas. 31 (2): 119–25. doi:10.1097/01.mpa.0000173459.81193.4d. PMID16024997. S2CID25132037.
Oh JH, Yang JO, Hahn Y, Kim MR, Byun SS, Jeon YJ, et al. (December 2005). "Transcriptome analysis of human gastric cancer". Mammalian Genome. 16 (12): 942–54. doi:10.1007/s00335-005-0075-2. PMID16341674. S2CID69278.
Grubbs EG, Abdel-Wahab Z, Tyler DS, Pruitt SK (December 2006). "Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer". Annals of Surgical Oncology. 13 (12): 1645–54. doi:10.1245/s10434-006-9029-5. PMID16957968. S2CID8003703.
Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, et al. (July 2007). "Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells". The Prostate. 67 (10): 1121–31. doi:10.1002/pros.20608. PMID17492652. S2CID30518541.